Comparison of postoperative NLR, PLR, and SII between the two groups. by Changxu Wang (17826805)

Subjects:

Adjusted HR (95% CIs) for 28-day all-cause mortality according to RDW trajectories in subgroups analyses*. by Riming He (18021538)

Subjects:

Establishment of a diabetic rat model. by Lan Zeng (638254)

Subjects:

Effect of <i>slc43a3</i> deletion on food and water consumption in male and female WT and KO mice. by Aaron L. Sayler (19797446)

Subjects:

Surgery design. by Maria Nadinskaia (22662419)

Subjects:

Effect of <i>slc43a3</i> deletion on resting blood pressure (systolic and diastolic) and heart rate of male and female WT and KO mice. by Aaron L. Sayler (19797446)

Subjects:

Phase analysis data and within group correlations. by Aaron L. Sayler (19797446)

Subjects:

Effect of <i>slc43a3</i> deletion on the diurnal cycle of oxygen consumption (VO₂) in male and female mice. by Aaron L. Sayler (19797446)

Subjects:

Pathophysiological mechanisms linking hyperammonemia to sarcopenia and cerebral changes. by Maria Nadinskaia (22662419)

Subjects:

Effect of <i>slc43a3</i> deletion on physical activity of male and female WT and KO mice. by Aaron L. Sayler (19797446)

Subjects:

Supporting information – data for plots. by Maria Nadinskaia (22662419)

Subjects:

Summary of measured parameters. by Aaron L. Sayler (19797446)

Subjects:

Morphometric analysis of histological slides in sarcopenia modeling by portal vein ligation and pyloric vein ligation. by Maria Nadinskaia (22662419)

Subjects:

Effect of <i>slc43a3</i> deletion on metabolic performance parameters in male and female WT and KO mice. by Aaron L. Sayler (19797446)

Subjects:

Raw data. by Aaron L. Sayler (19797446)

Subjects:

Liver and spleen mass in sarcopenia-hyperammonemia modelling on Day 30. by Maria Nadinskaia (22662419)

Subjects:

Increasing membrane permeability is sufficient to support MCPyV nuclear entry. by Karen Wang (288073)

Flow chart of inclusion and exclusion criteria. by Ho Geol Woo (7180775)

“…Contrary to AD, treatment of VV group was significantly associated with decreased risk of VD (HR: 0.566, 95% CI: 0.382–0.841). …”

Baseline characteristics of study participants. by Ho Geol Woo (7180775)

“…Contrary to AD, treatment of VV group was significantly associated with decreased risk of VD (HR: 0.566, 95% CI: 0.382–0.841). …”

Time series comparing trends at HSJ and control hospitals in the pre-intervention and intervention period. Significance test determine if trends differ between groups. by Eva Rydahl (6260771)

Subjects: